Leerink cautious on Intercept ahead of FLINT data Leerink initiated shares of Intercept with a Market Perform rating saying it is cautious ahead of the full FLINT data. The firmís talks with a specialist indicated that robust improvements in fibrosis are required to offset concerns about plasma lipids and excess cardiovascular events. Leerink set a $270 price target for the stock. Shares of Intercept were also initiated this morning at Nomura with a Neutral rating.
Deutsche Bank biotech analyst holds an analyst/industry conference call Biotech Analyst Young provides a review of the ICPT/GNFT thesis on an Analyst/Industry conference call to be held on October 22 at 11 am.